These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 2982100)

  • 1. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist.
    Miller WR; Scott WN; Morris R; Fraser HM; Sharpe RM
    Nature; 1985 Jan 17-23; 313(5999):231-3. PubMed ID: 2982100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells.
    Blankenstein MA; Henkelman MS; Klijn JG
    Eur J Cancer Clin Oncol; 1985 Dec; 21(12):1493-9. PubMed ID: 3938397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
    Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
    J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers.
    Emons G; Schally AV
    Hum Reprod; 1994 Jul; 9(7):1364-79. PubMed ID: 7962452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.
    Dondi D; Limonta P; Moretti RM; Marelli MM; Garattini E; Motta M
    Cancer Res; 1994 Aug; 54(15):4091-5. PubMed ID: 8033142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
    Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
    Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations.
    Stoeckemann K; Sandow J
    J Cancer Res Clin Oncol; 1993; 119(8):457-62. PubMed ID: 8509436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line.
    Arencibia JM; Schally AV
    Int J Oncol; 2000 May; 16(5):1009-13. PubMed ID: 10762638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor and endocrine effects of chronic LHRH agonist treatment (Buserelin) with or without tamoxifen in premenopausal metastatic breast cancer.
    Klijn JG; de Jong FH; Blankenstein MA; Docter R; Alexieva-Figusch J; Blonk-van der Wijst J; Lamberts SW
    Breast Cancer Res Treat; 1984; 4(3):209-20. PubMed ID: 6435703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the direct action of luteinizing hormone-releasing hormone agonists at the testicular level in intact rats treated with an antiluteinizing hormone serum.
    Séguin C; Bélanger A; Labrie F; Hansel W
    Endocrinology; 1982 Feb; 110(2):524-30. PubMed ID: 6276140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gonadotropin-releasing hormone and its agonists on prolactin secretion from normal and tumorous pituitary cells.
    Lamberts SW; Uitterlinden P; Reubi JC; de Jong FH
    Neuroendocrinology; 1989 Feb; 49(2):157-63. PubMed ID: 2524674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP.
    Limonta P; Dondi D; Moretti RM; Maggi R; Motta M
    J Clin Endocrinol Metab; 1992 Jul; 75(1):207-12. PubMed ID: 1320049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of LHRH and somatostatin analogs on human breast cancer.
    Brower ST; Schally AV; Redding TW; Hollander VP
    J Surg Res; 1992 Jan; 52(1):6-14. PubMed ID: 1347798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.
    Engel JB; Schally AV
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):157-67. PubMed ID: 17237842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors.
    Hershkovitz E; Marbach M; Bosin E; Levy J; Roberts CT; LeRoith D; Schally AV; Sharoni Y
    J Clin Endocrinol Metab; 1993 Oct; 77(4):963-8. PubMed ID: 8408472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers.
    Gründker C; Völker P; Schulz KD; Emons G
    Gynecol Oncol; 2000 Aug; 78(2):194-202. PubMed ID: 10926802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of pituitary luteinizing hormone releasing hormone receptors by sex steroids and luteinizing hormone releasing hormone in the rat.
    Marchetti B; Reeves JJ; Pelletier G; Labrie F
    Biol Reprod; 1982 Aug; 27(1):133-45. PubMed ID: 6288128
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the GnRH antagonist cetrorelix using a female rat model.
    Roth C; Leonhardt S; Seidel C; Luft H; Wuttke W; Jarry H
    Pediatr Res; 2000 Oct; 48(4):468-74. PubMed ID: 11004237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
    ; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
    Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.